IgG and Anti-IgE Antibody Combination for Hypersensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Type I hypersensitivity reactions, such as allergies, often lower serum IgE levels significantly, increasing the risk of cancer due to compromised anti-tumor surveillance, and may not provide complete protection against allergen exposure.
Innovation Solution
Combining anti-allergen IgG antibodies with anti-IgE antibodies that inhibit IgE binding to the high affinity FcεRI receptor, reducing the severity of hypersensitivity reactions without eliminating circulating IgE, thereby maintaining immune surveillance for tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If anti-IgE antibodies are used to lower serum IgE levels significantly, then allergic responses are reduced, but the risk of cancer increases due to compromised anti-tumor surveillance
Solution Approach 1:
The patent applies local quality by using allergen-specific IgG antibodies that target only the specific allergen causing the allergic reaction, rather than systemically suppressing all IgE antibodies. This localized approach reduces allergic responses to the specific allergen while preserving overall IgE-mediated anti-tumor surveillance functions in the immune system.
Solution Approach 2:
The patent changes the parameter of IgG antibody distribution by inducing high levels of allergen-specific IgG antibodies through immunization or therapeutic administration. This increases the concentration of protective IgG antibodies at the specific allergen interface without requiring systemic suppression of IgE levels, thereby maintaining the balance between allergy protection and cancer surveillance.
2Object-affected harmful factors
If IgE levels are reduced to prevent allergic reactions, then hypersensitivity is controlled, but complete protection against allergen exposure is not achieved
Solution Approach 1:
The patent employs a composite immunological approach by combining both IgE and IgG antibody responses. The immune system is stimulated to produce both IgE antibodies (which provide some protective function) and high levels of allergen-specific IgG antibodies (which block allergic reactions). This composite antibody profile provides more complete and reliable protection than IgE suppression alone.
Solution Approach 2:
The patent introduces allergen-specific IgG antibodies as an intermediary protective mechanism. These IgG antibodies act as mediators that bind to allergens and prevent them from interacting with IgE antibodies and FcεRI receptors on mast cells and basophils. This intermediary IgG layer provides reliable protection while allowing IgE levels to remain at physiologically functional levels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces the severity of allergic responses while minimizing the risk of cancer by maintaining balanced IgE-mediated immune function, providing significant reduction in allergic symptoms without exposing patients to increased cancer risk.
Implementation Method 1
an anti-IgE antibody that inhibits IgE binding to the high affinity FcεRI receptor
Implementation Method 2
an IgG antibody that binds to an epitope on an allergen
Data Source
AI summary
The present invention provides compositions and methods for preventing an anaphylactoid hypersensitivity reaction in a subject by providing to that subject a combination of antigen-binding IgG and an anti-IgE antibody.